EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Discovery of Highly Potent and BMPR2-Selective Kinase Inhibitors Using DNA-Encoded Chemical Library Screening

Ram K Modukuri iD, Diana Monsivais, Feng Li, Murugesan Palaniappan, Kurt M Bohren, Zhi Tan, Angela F Ku, Yong Wang, Chandrashekhar Madasu, Jian-Yuan Li, Suni Tang, Gabriella Miklossy und 3 weitere

Journal of Medicinal Chemistry · 09.02.2023 · 66 (3) · 2143-2160

DOI: 10.1021/acs.jmedchem.2c01886 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 31.01.2023. Verfasst von Ram K Modukuri und 14 weiteren Autor:innen. Beteiligte Einrichtung: Center for Drug Discovery, Department of Pathology & Immunology, Baylor College of Medicine, Houston, Texas77030, United States. Hauptthemen laut MEDLINE: Signal Transduction, DNA. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NICHD NIH HHS, NCI NIH HHS, NIDDK NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The discovery of monokinase-selective inhibitors for patients is challenging because the 500+ kinases encoded by the human genome share highly conserved catalytic domains. Until now, no selective inhibitors unique for a single transforming growth factor β (TGFβ) family transmembrane receptor kinase, including bone morphogenetic protein receptor type 2 (BMPR2), have been reported. This dearth of receptor-specific kinase inhibitors hinders therapeutic options for skeletal defects and cancer as a result of an overactivated BMP signaling pathway. By screening 4.17 billion "unbiased" and "kinase-biased" DNA-encoded chemical library molecules, we identified hits CDD-1115 and CDD-1431, respectively, that were low-nanomolar selective kinase inhibitors of BMPR2. Structure-activity relationship studies addressed metabolic lability and high-molecular-weight issues, resulting in potent and BMPR2-selective inhibitor analogs CDD-1281 (IC50 = 1.2 nM) and CDD-1653 (IC50 = 2.8 nM), respectively. Our work demonstrates that DNA-encoded chemistry technology (DEC-Tec) is reliable for identifying novel first-in-class, highly potent, and selective kinase inhibitors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Signal TransductionDNAHumansGene LibraryBone Morphogenetic Protein Receptors, Type II

Substanzen

DNABMPR2 protein, humanBone Morphogenetic Protein Receptors, Type II

Autor:innen und Institutionen

  • Center for Drug Discovery, Department of Pathology & Immunology, Baylor College of Medicine, Houston, Texas77030, United States.
  • Department of Pharmacology and Chemical Biology, Baylor College of Medicine, Houston, Texas77030, United States.

ORCID-Profile: Ram K Modukuri, Martin M Matzuk

Förderung

  • NICHD NIH HHS
  • NCI NIH HHS
  • NIDDK NIH HHS
  • Cancer Prevention and Research Institute of Texas
  • U.S. Department of Health and Human Services

Zitieren

APA

Modukuri, R. K., Monsivais, D., Li, F., Palaniappan, M., Bohren, K. M., Tan, Z., Ku, A. F., Wang, Y., Madasu, C., Li, J. Y., Tang, S., Miklossy, G., Palmer, S. S., Young, D. W., & Matzuk, M. M. (2023). Discovery of Highly Potent and BMPR2-Selective Kinase Inhibitors Using DNA-Encoded Chemical Library Screening. Journal of Medicinal Chemistry, 66(3), 2143-2160. https://doi.org/10.1021/acs.jmedchem.2c01886

Vancouver

Modukuri RK, Monsivais D, Li F, Palaniappan M, Bohren KM, Tan Z, et al. Discovery of Highly Potent and BMPR2-Selective Kinase Inhibitors Using DNA-Encoded Chemical Library Screening. Journal of Medicinal Chemistry. 2023;66(3):2143-2160. doi:10.1021/acs.jmedchem.2c01886

BibTeX
@article{Modukuri2023,
  author = {Modukuri, Ram K and Monsivais, Diana and Li, Feng and Palaniappan, Murugesan and Bohren, Kurt M and Tan, Zhi and Ku, Angela F and Wang, Yong and Madasu, Chandrashekhar and Li, Jian-Yuan and Tang, Suni and Miklossy, Gabriella and Palmer, Stephen S and Young, Damian W and Matzuk, Martin M},
  title = {Discovery of Highly Potent and BMPR2-Selective Kinase Inhibitors Using DNA-Encoded Chemical Library Screening},
  journal = {Journal of Medicinal Chemistry},
  year = {2023},
  volume = {66},
  number = {3},
  pages = {2143--2160},
  doi = {10.1021/acs.jmedchem.2c01886}
}
Kostenlos starten →